Evidence map›Paper›PMID 39900503›Full record

ArticlePhotochemistry and photobiology

A novel acquired resistance mechanism to 5-aminolevulinic acid-mediated photodynamic therapy with ABCG2 inhibition.

Sharayu Chandratre, Jordyn Olsen, Bin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sharayu ChandratreDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, Pennsylvania, USA.
Jordyn OlsenDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, Pennsylvania, USA.
Bin ChenDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-7736-4158

Funding

Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatmentR15CA268200 · NCI · UNIVERSITY OF THE SCIENCES PHILADELPHIA · PI CHEN, BIN · 2022 to 2023
$554k
Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatmentR15EB026208 · NIBIB · UNIVERSITY OF THE SCIENCES PHILADELPHIA · PI CHEN, BIN · 2018 to 2018
$356k
NCI NIH HHS R15 CA268200NIBIB NIH HHS R15 EB026208NIH HHS R15CA268200
6 · The paper itself

Abstract

We report the occurrence of acquired tumor cell resistance to 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) in combination with ABCG2 inhibition. ALA-PDT in combination with either an ABCG2 tool inhibitor Ko143 or a repurposed clinically-relevant ABCG2 inhibitor lapatinib was highly effective in eradicating the H4 human glioma cells, resulting in minimal cell survival after treatment. However, after seven rounds of repeated treatments with light dose escalation, the resultant tumor cells became resistant to the combination therapy. The resistant sublines and the parental cell line showed similar ABCG2 activities and protein levels, indicating that it was not ABCG2 that caused the resistance. They also exhibited similar responses to PpIX-PDT and mTOR inhibitor AZD2014, suggesting that alterations in PDT sensitivity and mTOR pathway had little contribution to the development of resistance phenotype. By determining the intracellular and extracellular PpIX levels, the activities and protein levels of heme biosynthesis enzymes, we found that porphobilinogen deaminase (PBGD) activity and protein level were significantly reduced in the resistant sublines, causing resistance to PDT by substantially reducing PpIX biosynthesis. A novel acquired resistance mechanism to ALA-PDT with ABCG2 inhibition has been uncovered.

Indexed as

Aminolevulinic AcidATP Binding Cassette Transporter, Subfamily G, Member 2Drug Resistance, NeoplasmNeoplasm ProteinsPhotochemotherapyPhotosensitizing AgentsCell Line, TumorDiketopiperazinesHeterocyclic Compounds, 4 or More RingsHumansProtoporphyrins3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl esterABCG2 protein, humanAminolevulinic AcidATP Binding Cassette Transporter, Subfamily G, Member 2DiketopiperazinesHeterocyclic Compounds, 4 or More RingsNeoplasm ProteinsPhotosensitizing Agentsprotoporphyrin IXProtoporphyrins5‐aminolevulinic acid (ALA)ABCG2heme biosynthesis pathwayhydroxymethylbilane synthase (HMBS)photodynamic therapy (PDT)porphobilinogen deaminase (PBGD)protoporphyrin IX (PpIX)

Identifiers

PMID39900503
PMCPMC12318111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.